Net Cash Provided by (Used in) Financing Activities of IMMUNIC, INC. from 31 Dec 2016 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
IMMUNIC, INC. annual and quarterly Net Cash Provided by (Used in) Financing Activities in USD history and change rate from 31 Dec 2016 to 31 Dec 2025.
  • IMMUNIC, INC. Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Mar 2025 was $0, a 100% decline year-over-year.
  • IMMUNIC, INC. annual Net Cash Provided by (Used in) Financing Activities for 2025 was $65,577,000, a 12% decline from 2024.
  • IMMUNIC, INC. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $74,541,000, a 7116% increase from 2023.
  • IMMUNIC, INC. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $1,033,000, a 99% decline from 2022.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)

IMMUNIC, INC. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $65,577,000 -$8,964,000 -12% 01 Jan 2025 31 Dec 2025 10-K 26 Feb 2026 2025 FY
2024 $74,541,000 +$73,508,000 +7116% 01 Jan 2024 31 Dec 2024 10-K 26 Feb 2026 2025 FY
2023 $1,033,000 -$94,727,000 -99% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
2022 $95,760,000 +$52,919,000 +124% 01 Jan 2022 31 Dec 2022 10-K 22 Feb 2024 2023 FY
2021 $42,841,000 -$101,590,000 -70% 01 Jan 2021 31 Dec 2021 10-K 23 Feb 2023 2022 FY
2020 $144,431,000 +$109,536,000 +314% 01 Jan 2020 31 Dec 2020 10-K 24 Feb 2022 2021 FY
2019 $34,895,000 +$15,639,000 +81% 01 Jan 2019 31 Dec 2019 10-K 26 Feb 2021 2020 FY
2018 $19,256,000 -$18,728,000 -49% 01 Jan 2018 31 Dec 2018 10-K 16 Mar 2020 2019 FY
2017 $37,984,000 +$25,610,000 +207% 01 Jan 2017 31 Dec 2017 10-K 04 Mar 2019 2018 FY
2016 $12,374,000 01 Jan 2016 31 Dec 2016 10-K 04 Mar 2019 2018 FY

IMMUNIC, INC. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $0 -$74,464,000 -100% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q1 2024 $74,464,000 +$74,413,000 +145908% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025 2025 Q1
Q1 2023 $51,000 -$29,592,000 -100% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q1 2022 $29,643,000 +$29,643,000 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q1 2021 $0 -$568,000 -100% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q1 2020 $568,000 -$19,963,000 -97% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q1 2019 $20,531,000 +$50,531,000 01 Jan 2019 31 Mar 2019 10-Q 08 May 2020 2020 Q1
Q1 2018 $30,000,000 01 Jan 2018 31 Mar 2018 10-Q 10 Apr 2019 2019 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.